AI-guided health recommendations for gastric cancer prevention
Interventional Study Focused on Providing Personalised Health Recommendations to the General Population Through an Integrated AI Guided App as a Strategy for Gastric Cancer Prevention (AIDA)
This study is testing an AI tool that helps doctors spot early signs of stomach issues and gives personalized advice to prevent gastric cancer.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 450 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Fundación para la Investigación del Hospital Clínico de Valencia Academic / other |
| Locations | 1 site (Valencia) |
| Trial ID | NCT06421324 on ClinicalTrials.gov |
What this trial studies
This clinical study aims to implement and validate the AIDA tool, an AI-powered assistant designed to help clinicians diagnose precancerous inflammation and suggest personalized therapeutic strategies. The study is conducted in two phases: the first focuses on risk stratification and personalized recommendations, while the second involves the development and testing of a mechanistic model. By integrating AI technology, the study seeks to enhance patient monitoring and contribute to gastric cancer prevention efforts.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with a diagnosis of gastric intestinal metaplasia or a history of H. pylori infection who require a gastroscopy.
Not a fit: Patients undergoing endoscopy for unrelated conditions or those with other gastric diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide personalized health recommendations that significantly improve early detection and prevention of gastric cancer.
How similar studies have performed: While the use of AI in healthcare is growing, this specific approach to gastric cancer prevention through personalized recommendations is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Subjects ≥ 18 years old with a diagnosis of GIM or previous or current H. pylori infection, to whom a gastroscopy is indicated within clinical care * Availability of a signed informed consent form to participate in the study Exclusion Criteria: * Patients to whom an endoscopy is performed for the follow-up of another illness such as oesophageal varices and/or for therapy such as endoscopic dilation, feeding tube placement or endoscopic resection * Subjects with a clinical diagnosis of gastric diseases other than GIM or GC * Patients who have received antimicrobials during the four weeks prior to the endoscopy * Patients who have received proton pump inhibitors and/or bismuth-based treatments at least two weeks prior to the endoscopy * Subjects for whom clinical data are not available: H. pylori status, eradication treatment, sex, age, tobacco smoking, and first-degree family history of gastric cancer * Subjects who lack the mental capacity to understand the nature and requirements of the study and who lack the ability to give informed consent
Where this trial is running
Valencia
- Hospital Clínico Universitario de Valencia — Valencia, Spain (Recruiting)
Study contacts
- Principal investigator: Tania Fleitas, MD, PhD — Fundación para la Investigación del Hospital Clínico de Valencia
- Study coordinator: Ana Miralles Marco, PhD
- Email: amiralles@incliva.es
- Phone: +34 689567412
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.